Raphanus Sativus

Radish (Raphanus sativus) allergenic extract is a non-standardized biological product used for the diagnosis and treatment of specific IgE-mediated allergies. It belongs to the Non-Standardized Food Allergenic Extract class.

Dosage for Radish allergenic extract is highly individualized and depends entirely on the patient's level of sensitivity and the method of administration. There is no 'standard' dose because the extract is non-standardized, meaning the potency can vary between lots.

Diagnostic Dosing (Skin Prick Test)

For the Skin Prick Test (SPT), a single drop of the 1:10 or 1:20 w/v (weight/volume) glycerinated extract is applied to the skin (usually the forearm or back). A sterile lancet is then used to prick the skin through the drop. A positive control (histamine) and a negative control (saline/glycerin) are used simultaneously. The results are read 15 to 20 minutes later.

Therapeutic Dosing (Immunotherapy)

If used for immunotherapy, the protocol typically involves two phases:

1. 1Build-up Phase: Starting with a highly dilute solution (e.g., 1:100,000 or 1:10,000), injections are given once or twice weekly. The dose is incrementally increased (often doubling) until the 'maintenance dose' is reached.
2. 2Maintenance Phase: Once the maximum tolerated dose is achieved, the frequency of injections is reduced to once every 2 to 4 weeks. This phase may continue for 3 to 5 years.

Radish allergenic extract is generally considered safe for use in children, provided it is administered by a pediatric allergist.

• Infants and Toddlers: Skin testing may be performed, though the reactivity of the skin may be lower than in adults. Dosing for immunotherapy in children follows the same escalation principles as adults but requires even more vigilant monitoring for systemic reactions.
• Safety Note: Immunotherapy is rarely initiated in children under the age of 5 due to the difficulty of communicating early symptoms of systemic reactions.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the systemic load of the protein is minimal. However, patients with end-stage renal disease may have altered skin reactivity (uremic pruritus), which can make skin test interpretation difficult.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins is not dependent on hepatic enzyme systems.

Elderly Patients

In patients over 65, skin reactivity often decreases due to changes in skin turgor and reduced mast cell density. Healthcare providers may need to interpret 'smaller' wheals as clinically significant. Additionally, the risk of cardiac complications during a systemic reaction is higher in this population.

Radish allergenic extract is never self-administered for diagnostic purposes. It must be administered by a trained healthcare professional (usually an allergy nurse or physician).

• Preparation: The skin site should be cleaned with alcohol and allowed to dry.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Exposure to heat or freezing can denature the proteins, rendering the extract ineffective or dangerously unpredictable.
• Observation: After any administration (test or injection), the patient must remain in the clinic for at least 30 minutes to be monitored for signs of anaphylaxis.

In the context of immunotherapy, a missed dose can disrupt the desensitization process.

• If a dose is missed by a few days, the same dose may often be given.
• If a dose is missed by more than a week, the healthcare provider may need to reduce the dose to the previous level or lower to ensure safety before resuming the build-up.

An 'overdose' in the context of Radish extract refers to the administration of a concentration higher than the patient's threshold of tolerance.

• Signs: Rapid onset of generalized itching, hives, swelling of the throat, wheezing, or a drop in blood pressure.
• Emergency Measures: Immediate administration of intramuscular epinephrine (0.3 mg for adults, 0.15 mg for children) is the first-line treatment. Oxygen, intravenous fluids, and antihistamines may also be required.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients undergoing testing or treatment with Radish allergenic extract will experience some form of local reaction. These are generally expected and indicate the extract is biologically active.

• Local Wheal and Flare: Within 15-20 minutes of a skin test, a small, itchy bump (wheal) surrounded by redness (flare) is normal. This typically resolves within 1 to 2 hours.
• Injection Site Itching: For those receiving immunotherapy, mild itching at the site of the subcutaneous injection is very common.
• Local Swelling: A small amount of swelling (less than the size of a half-dollar) at the injection site that appears several hours later is common and can be managed with cold compresses.

Radish allergenic extract is a potent biological substance. It is not a 'natural' remedy in the sense of being harmless; it is a concentrated form of allergens that can trigger profound physiological responses. It must always be used under the supervision of a board-certified allergist/immunologist.

No FDA black box warnings for Radish are specifically listed as a unique entity, but it falls under the General Black Box Warning for Allergenic Extracts. The warning emphasizes that:

1. 1This product can cause severe anaphylaxis.
2. 2Injections should only be given in facilities equipped with emergency supplies (epinephrine, oxygen, IV fluids).
3. 3

There are no absolute drug-drug contraindications that prevent the use of Radish extract, but certain combinations make its use unacceptably dangerous:

• Beta-Blockers and Allergen Immunotherapy: While not strictly contraindicated in all cases, the combination is generally avoided because beta-blockers inhibit the action of epinephrine, the only life-saving treatment for the anaphylaxis that the extract might cause.

• MAO Inhibitors (MAOIs): Drugs like phenelzine or tranylcypromine can potentiate the effects of sympathomimetics (like epinephrine). If a patient on an MAOI has a reaction to Radish extract, the emergency treatment could lead to a hypertensive crisis.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs like amitriptyline can increase the cardiovascular sensitivity to epinephrine.

Radish allergenic extract must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) consistently below 70% of predicted values are at an unacceptably high risk of fatal bronchospasm if a systemic reaction occurs.
2. 2Previous Life-Threatening Reaction: If a patient has previously experienced a Grade 4 systemic reaction (anaphylactic shock) to Radish extract, further use is strictly contraindicated.
3. 3Acute Illness: Testing or treatment should not be performed if the patient has a fever, acute infection, or is in the midst of an organ transplant rejection episode.

Radish allergenic extract is typically classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.

• Teratogenicity: There is no evidence that the proteins in Radish extract are teratogenic (cause birth defects).
• Risks: The primary danger is not the extract itself, but the potential for anaphylaxis in the mother. Anaphylaxis leads to maternal hypotension (low blood pressure), which can cause immediate and severe fetal hypoxia (lack of oxygen to the baby).
• Clinical Practice: Allergists generally do not start new immunotherapy during pregnancy but may continue maintenance doses if the risk of a reaction is low.

It is not known whether the components of Radish extract are excreted in human milk. However, because these are large proteins that are digested in the gastrointestinal tract, it is highly unlikely that they would affect a nursing infant. The American Academy of Allergy, Asthma & Immunology (AAAAI) generally considers allergen immunotherapy compatible with breastfeeding.

Radish allergenic extract acts as a specific antigen that probes the presence of sensitized mast cells. At the molecular level, the extract contains various proteins, notably Rap s 1 (a 2S albumin storage protein). Upon introduction into the dermis, these proteins bind to the Fab portion of IgE antibodies. These IgE antibodies are already 'sensitized' and anchored to the high-affinity FcεRI receptors on mast cells.

The binding of a single radish protein molecule to two adjacent IgE molecules (cross-linking) triggers the aggregation of FcεRI receptors. This activates intracellular signaling via the ITAM (Immunoreceptor Tyrosine-based Activation Motif), leading to a rapid influx of calcium and the release of histamine from storage granules.

• Dose-Response: There is a clear dose-response relationship between the concentration of the extract and the size of the wheal, up to a 'saturation point' where all available IgE sites are occupied.
• Time to Onset